NCT04644016View on ClinicalTrials.gov

Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders

PHASE2RecruitingINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

November 20, 2020

Primary Completion Date

December 20, 2025

Study Completion Date

December 20, 2025

Conditions
AMLALLMDSMPD Withou MyelofibrosisNHL or HLInherited Metabolic DisordersHemoglobinopathiesBone Marrow FailureHLH
Interventions
DRUG

Clofarabine

Clofarabine

DRUG

Fludarabine

Fludarabine

DRUG

Busulfan

Busulfan per PK

DRUG

Cyclosporine-A

GVHD prophylaxis will consist of cyclosporine-A (CSA) and mycophenolate mofetil (MMF) starting day -3.

DRUG

Mycophenolate Mofetil

GVHD prophylaxis will consist of cyclosporine-A (CSA) and mycophenolate mofetil (MMF) starting day -3.

BIOLOGICAL

Cord Blood Graft

The CB graft will be infused on day 0 per standard practice

Trial Locations (1)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT04644016 - Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders | Biotech Hunter | Biotech Hunter